No Data
No Data
No Data
No Data
No Data
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 22:29
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
BenzingaApr 12 20:09
Insiders Buying GameStop And 2 Other Stocks
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
BenzingaApr 10 20:11
PepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of
GlobeNewswireMar 14 04:05
PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
PepGen Receives U.S. FDA Orphan Drug And Rare Pediatric Disease Designations For PGN-EDO51 For The Treatment Of Duchenne Muscular Dystrophy
BenzingaMar 13 19:01
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. (Nasdaq: PEPG) today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutations are amenable to an exon 51 skipping approach. PepGen is evaluating PGN-EDO51 for the treatment of DMD in the ongoing CONNECT1 Phase 2 trial, and expects to begin enrolling patients in the CONNECT2 Phase 2 trial later this year.
GlobeNewswireMar 13 19:00
No Data
No Data